4//SEC Filing
Stoppel Laura 4
Accession 0001415889-25-018280
CIK 0001817241other
Filed
Jun 25, 8:00 PM ET
Accepted
Jun 26, 4:30 PM ET
Size
6.3 KB
Accession
0001415889-25-018280
Insider Transaction Report
Form 4
Stoppel Laura
Director
Transactions
- Award
Director Stock Option (Right to Buy)
2025-06-24+13,750→ 13,750 totalExercise: $1.61Exp: 2035-06-23→ Common Stock (13,750 underlying)
Footnotes (2)
- [F1]The shares subject to the option will vest in full on the earlier of June 24, 2026, or the date of the Issuer's 2026 annual stockholder meeting.
- [F2]Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the R.A. Capital Healthcare Fund, L.P. (the "Fund"), the R.A. Capital Nexus Fund, L.P. (the "Nexus Fund"), the RA Capital Nexus Fund III, L.P. (the "Nexus Fund III") and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund III and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.
Documents
Issuer
Artiva Biotherapeutics, Inc.
CIK 0001817241
Entity typeother
Related Parties
1- filerCIK 0001865119
Filing Metadata
- Form type
- 4
- Filed
- Jun 25, 8:00 PM ET
- Accepted
- Jun 26, 4:30 PM ET
- Size
- 6.3 KB